PE 0139

Drug Profile

PE 0139

Alternative Names: Insumera; PE 0139

Latest Information Update: 05 May 2016

Price : $50

At a glance

  • Originator PhaseBio Pharmaceuticals
  • Class Antihyperglycaemics; Biopolymers; Drug conjugates; Insulins; Pancreatic hormones; Recombinant fusion proteins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 05 May 2016 PhaseBio plans a clinical trial in Type 2 Diabetes (PhaseBio pipeline, May 2016)
  • 01 Oct 2015 Phase-II clinical trials in Type-2 diabetes mellitus in USA (SC)
  • 07 Jun 2015 Adverse events data from a phase I trial in Type II diabetes mellitus released by PhaseBio Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top